Physician profile
Srikanth Naramala
NPI 1437412129
$20,716.49
in general payments reported to CMS, 2019-2025
23 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $37.66 · 2021: $114 · 2022: $504 · 2023: $16K · 2024: $2,331 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $13K · Food and Beverage: $5,558 · Travel and Lodging: $1,478 · Education: $53.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $12,600.00 |
| Food and Beverage | $5,558.01 |
| Travel and Lodging | $1,477.62 |
| Education | $53.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $15,130.29 | 2021-2024 | Lupkynis |
| Abbvie INC. | $1,813.52 | 2019-2025 | |
| Amgen INC. | $955.75 | 2019-2025 | Tavneos, Evenity, Prolia |
| Pfizer INC. | $490.33 | 2019-2025 | |
| Janssen Biotech, INC. | $423.21 | 2022-2024 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $314.79 | 2019-2025 | Benlysta |
| Ucb, INC. | $240.84 | 2023-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.44 | 2023-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $207.83 | 2022-2024 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $206.82 | 2023-2025 | |
| Radius Health, INC. | $157.38 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.93 | 2024-2025 | Orencia |
| Lilly USA, LLC | $112.91 | 2022-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $75.01 | 2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $50.18 | 2022-2023 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $38.30 | 2023 | Yuflyma |
| Genzyme Corporation | $33.22 | 2023 | |
| Alexion Pharmaceuticals, INC. | $25.74 | 2024 | Strensiq |
| Genentech USA, INC. | $23.68 | 2024 | Actemra |
| Organon LLC | $22.43 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $22.04 | 2023 | Arcalyst |
| Octapharma USA, INC. | $20.90 | 2024 | Octagam Immune Globulin (Human) |
| Csl Behring | $18.95 | 2025 | Haegarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Naramala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.